Join the Maine Immunization Program for a Back-to-School Lunch and Learn Webinar on Wednesday, August 20, 2025 @ 12:00 PM – 1:00 PM. This educational webinar will cover required school vaccines, routine recommended vaccines by age group and how to help children catch up on missed vaccines.
This webinar will also provide an overview of Maine’s School Immunization requirements and the vaccination schedule for childhood and adolescent age groups, including vaccines to protect against HPV and Men B. A Q&A session will follow the presentation.
Join the Maine Immunization Program (MIP) for our annual Respiratory Season Educational Lunch and Learn Webinar on Thursday, September 18, 2025 @ 12:00 PM hosted by MIP's VFC and Adult Education teams.
Topics will include:
overview of vaccines available through VFC and Adult 317 Program for 2025 – 2026 respiratory season.
Introduction to the NEWEST RSV monoclonal antibody product, Enflonsia (clesrovimab)for infants.
MIP will update providers once ordering is available through ImmPact.
Updated recommendations for influenza, COVID-19, and RSV (including Beyfortus for infants).
The CDC has officially accepted the ACIP recommendations from the June 25-26 meeting.
Key updates include:
Clesrovimab (Enflonsia, Merck) is now an approved option for preventing RSV in infants younger than 8 months born during or entering their first RSV season.
There is no preference between clesrovimab and nirsevimab (Sanofi) for eligible infants.
Only nirsevimab is recommended for older infants and toddlers at high risk entering their second RSV season.
Additionally, the annual influenza vaccination recommendation for everyone aged 6 months and older (without contraindications) has been formally accepted for the 2025-2026 season. This includes guidance to use flu vaccines that do not contain thimerosal as a preservative.
All June ACIP recommendations are now official, Immunize.org is updating its materials to reflect these changes.
CDC released four new at-a-glance resources for healthcare professionals on RSV prevention products. Each 2-page document addresses a single product. Use these resources to help your clinical team prepare for RSV prevention in adults and infants this fall. These materials are available on the CDC’s main Respiratory Syncytial Virus (RSV) Immunizationsmain page and include the following documents:
The CDC has informed state and local immunization programs that there may be changes to pediatric COVID-19 vaccine availability for the upcoming 2025-2026 season:
Pfizer’s COVID-19 vaccinefor 6m–4y may not be renewed under Emergency Use Authorization (EUA) for the upcoming season.
For ages 5-11, Pfizer is aiming for full FDA licensure soon, pending regulatory approval.
Moderna’s Spikevax® has full licensure for children with certain health conditions and is awaiting approval for its updated 2025-2026 version. Moderna intends to boost supply for kids 11 and under to fill any gaps.
Novavax’s vaccine continues to be available for children aged 12+ with certain health conditions.
CDC is actively working with Moderna to finalize supply and distribution plans, especially in light of rising COVID-19 activity and potential supply concerns this fall.
More updates will be shared as information becomes available.
If you administer vaccines and work in pediatrics, obstetrics, family medicine, internal medicine, or pharmacy, you may qualify for 1 FREE continuing education credit from Johns Hopkins Medicine. This opportunity is available to the first 100 participants per specialty who complete a brief 5-minute follow-up survey about 3–6 months after finishing an online course.
The course, “How to Talk with Patients and Parents about COVID-19 Vaccines,” is provided by the Johns Hopkins Bloomberg School of Public Health’s Institute for Vaccine Safety. It consists of short modules that total 60 minutes (about 10 minutes each) and includes communication strategies like the "Presumptive Approach" and the "5-Step Strategy", which research has found to improve vaccine confidence and maintain patient autonomy.
The course is now available with and without credit at:
If you are interested, please contact Michelle Goryn at Johns Hopkins Bloomberg School of Public Health’s Institute for Vaccine Safety at mgoryn1@jh.edu.
Check out LetsGetRealAboutVaccines.org, a new, trustworthy, and parent-friendly website that delivers factual vaccine guidance. It equips both families and providers with tools to confidently advocate for childhood vaccination.
This week, they're highlighting the “Learn About Children’s Vaccines” section, found under the first menu tab. This section offers clear, factual information to help families separate fact from fiction and better understand why most parents choose to vaccinate their children.
If you have any questions, please contact the Maine Immunization Program at: Main Line: (207) 287-3746 ImmPact Helpdesk: (207) 287-3006 / Support/Education: (207) 287-9972
